Virpax Pharmaceuticals, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
OTC.Pink
S-1/A: Virpax Pharmaceuticals Seeks Up to $4.7 Million in Public Offering to Advance Drug Development
Virpax Pharmaceuticals is offering up to 2,415,459 shares of common stock and pre-funded warrants in a best efforts public offering to fund drug development and general corporate purposes.
OTC.Pink
Virpax Pharmaceuticals is seeking to raise capital through a best efforts offering of common stock and pre-funded warrants.
OTC.Pink
S-1/A: Virpax Pharmaceuticals Seeks Up to $5.5 Million in Public Offering to Advance Clinical Trials
Virpax Pharmaceuticals aims to raise capital through a public offering of common stock and pre-funded warrants to fund clinical trials and for general corporate purposes.
OTC.Pink
Virpax Pharmaceuticals is offering up to 16,849,200 shares of common stock and pre-funded warrants to raise capital for clinical trials, working capital, and general corporate purposes.
OTC.Pink
Virpax Pharmaceuticals is conducting a best-efforts public offering of common stock and pre-funded warrants to raise up to $6 million, as it faces financial difficulties and Nasdaq listing compliance issues.
OTC.Pink
Virpax Pharmaceuticals is offering up to 6,883,260 shares of common stock and pre-funded warrants in a best efforts offering to raise capital for clinical trials, working capital, and general corporate purposes.
OTC.Pink
S-1/A: Virpax Pharmaceuticals Seeks Up to $5 Million in Public Offering Amidst Financial Uncertainty
Virpax Pharmaceuticals is offering up to 8,650,520 shares of common stock and pre-funded warrants in a best efforts offering to raise capital for clinical trials and working capital, amidst concerns about its financial position and Nasdaq compliance.
OTC.Pink
Virpax Pharmaceuticals launches a best efforts offering of common stock and pre-funded warrants, aiming to raise approximately $4.5 million for clinical development and general corporate purposes.
OTC.Pink
S-1/A: Virpax Pharmaceuticals Seeks $7 Million in Best Efforts Offering to Advance Pain Management Pipeline
Virpax Pharmaceuticals launches a best efforts offering of common stock and pre-funded warrants to raise up to $7 million for clinical trials and corporate purposes.
OTC.Pink
Virpax Pharmaceuticals is launching a best efforts public offering of common stock and pre-funded warrants to fund its Probudur IND filing and for general corporate purposes.
OTC.Pink
Virpax Pharmaceuticals is launching a best efforts offering of common stock and warrants, aiming to raise approximately $4.4 million for working capital and general corporate purposes.
OTC.Pink
Virpax Pharmaceuticals is seeking to raise capital through an offering of common stock, warrants, and pre-funded warrants, aiming to bolster its financial position and advance its drug development programs.
OTC.Pink
Virpax Pharmaceuticals is offering up to 2,215,189 shares of common stock and accompanying warrants in a best efforts offering to raise capital for debt settlement, product development, and general corporate purposes, while facing Nasdaq compliance issues and ongoing litigation.
OTC.Pink
Virpax Pharmaceuticals launches a best efforts offering of common stock and warrants, aiming to raise up to $14 million to support product development, settle legal obligations, and bolster working capital.